Literature DB >> 10739299

Melatonin inhibits oxidative modification of low-density lipoprotein particles in normolipidemic post-menopausal women.

A Wakatsuki1, Y Okatani, N Ikenoue, C Izumiya, C Kaneda.   

Abstract

In this study, we investigated the short-term effect of melatonin on the susceptibility of low-density lipoprotein (LDL) to oxidation in normolipidemic post-menopausal women. Fifteen post-menopausal women received 6.0 mg melatonin daily for 2 wk. Blood samples were obtained before and after the treatment and the plasma levels of total cholesterol, total triglyceride, high-density lipoprotein (HDL)-cholesterol, LDL-cholesterol, LDL-triglyceride, and LDL-apolipoprotein B were determined. LDL oxidation was performed by incubation with copper ions and was analyzed by monitoring the kinetics of conjugated diene formation and measuring the concentration of thiobarbituric-acid-reactive substances (TBARS). LDL-apolipoprotein B derivatization was analyzed by measuring trinitrobenzene sulfonic acid (TNBS) reactivity. Melatonin treatment significantly increased the plasma triglyceride levels (P<0.05), but did not significantly alter the plasma levels of total cholesterol, HDL-cholesterol, or LDL-lipids. The kinetics analysis of conjugated diene production revealed that melatonin treatment significantly prolonged the lag time of conjugated diene formation (from 64.71+/-11.89 to 70.15+/-10.52 min, P<0.05). The oxidation rate and the amount of conjugated diene, however, did not change significantly. The TBARS concentration was significantly reduced by melatonin treatment (from 49.31+/-7.57 to 38.69+/-23.90 nM/mg LDL, P<0.05). Furthermore, melatonin treatment significantly reduced the copper-induced decrease of TNBS reactivity (from 79.43+/-6.19 to 86.50+/-9.07% at 1 hr and from 71.03+/-6.74 to 76.31+/-4.99% at 2 hr, P<0.05). These results indicate that melatonin treatment may reduce LDL susceptibility to oxidative modification in normolipidemic post-menopausal women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739299     DOI: 10.1034/j.1600-079x.2001.280302.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  4 in total

1.  Serum lipid levels in seasonal affective disorder.

Authors:  Edda Pjrek; Dietmar Winkler; David W Abramson; Anastasios Konstantinidis; Jürgen Stastny; Matthäus Willeit; Nicole Praschak-Rieder; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-05       Impact factor: 5.270

Review 2.  Melatonin, mitochondria and hypertension.

Authors:  Ovidiu C Baltatu; Fernanda G Amaral; Luciana A Campos; Jose Cipolla-Neto
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

3.  Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial.

Authors:  Abhinav Goyal; Paul D Terry; Hillary M Superak; Christine L Nell-Dybdahl; Ritam Chowdhury; Lawrence S Phillips; Michael H Kutner
Journal:  Diabetol Metab Syndr       Date:  2014-11-18       Impact factor: 3.320

Review 4.  Potentiating the Benefits of Melatonin through Chemical Functionalization: Possible Impact on Multifactorial Neurodegenerative Disorders.

Authors:  Annia Galano; Eduardo G Guzmán-López; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.